ELI LILLY & CO

Discover how Eli Lilly’s new FDA‑approved breast‑cancer combo, a 300 % GLP‑1 rally, and AI‑driven R&D keep the company at the top of oncology and drug‑pricing debates.

FDA approves Inluriyo + Verzenio for ESR1‑mutated breast cancer, giving patients a first‑line, oral combo that boosts progression‑free survival.

With a $3.8B acquisition of AtaiBeckley, Eli Lilly taps the $200B+ mental‑health market, speeding up novel depression therapies and diversifying beyond its traditional drugs.

Discover Eli Lilly’s latest earnings, weight‑loss momentum, and growth‑stock resilience, plus a new $8.6 M subsidiary milestone—key insights for investors.

How Eli Lilly’s $2.88 billion Merida acquisition will reshape the autoimmune market, boosting revenue and outpacing rivals with next‑gen biologics.

Discover how Eli Lilly’s FDA approval of Mounjaro (tirzepatide) for cardiovascular risk in type 2 diabetes gives it a unique edge over GLP‑1 rivals and boosts investor prospects.

Explore how Eli Lilly’s new UK weight‑loss drug Foundayo and $7B Kelonia deal are reshaping its portfolio, driving stock gains and positioning it for future growth.

Explore how Eli Lilly’s $7 billion bid for Kelonia Therapies and its mRNA vaccine partnership with Amplitude could reshape drug innovation, diversify revenue, and challenge industry rivals.

Discover how Eli Lilly’s $3.8 B psychedelic buy‑out and GLP‑1 push reshape the biopharma landscape, balancing high valuation with bold growth.

Explore how Eli Lilly’s $750 M U.S. manufacturing expansion boosts supply chain resilience and speeds its oncology‑diabetes pipeline.